Authors have demonstrated in melanomas wild type for NRAS and BRAF, that activating constitutively KIT mutations may be functionally equivalent to constitutive activation of the RAS-RAF-MEK-ERK pathway due to NRAS or BRAF [25]. This evidence concerns the gene MAP2K7 and melanoma.